^
    Back
    Association details:
    Biomarker:KIT exon 11 mutation
    Cancer:Melanoma
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

    Excerpt:
    ...(Continued 1) If 20 patients without tumors harboring exon 11 or 13 KIT mutation are enrolled and treated before the completion of the patient accrual of 30, only those with tumors harboring exon 11 or 13 KIT mutation will be enrolled....
    Trial ID:
    NCT01092728
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    ACS Publications
    Title:

    A phase II trial of dasatinib in advanced melanoma

    Excerpt:
    An exon 11 deletion mutation was found in one other patient who did not respond to dasatinib.
    DOI:
    10.1002/cncr.25766